Admission of New Ordinary Shares and New ISIN

Update on Hemogenyx Pharmaceuticals plc

LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024

Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”)(LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, wishes to provide a further update on the admission of the New Ordinary Shares (as defined below) further to the passing of all resolutions at its Extraordinary General Meeting (the “Meeting”) held on 9 December 2024.

At the Meeting, resolutions were passed to approve the subdivision and reclassification of the Company’s existing 1,401,815,988 ordinary shares (the “Existing Ordinary Shares”) by 1:2 so that each Existing Ordinary Share was subdivided and reclassified into 1 new ordinary share of £0.000025 each (the “New Ordinary Shares”) and 1 deferred share of £0.009975 each (the “Deferred Shares”), followed by a consolidation of the New Ordinary Shares by 400:1 so that every 400 New Ordinary Shares were consolidated into 1 New Ordinary Share of £0.01 each (the “Capital Reorganisation”).

This strategic move by Hemogenyx Pharmaceuticals marks a significant milestone in the company’s development, as it allows for a more efficient and structured distribution of shares, ultimately benefiting shareholders and enhancing the company’s financial stability.

Impact on Individuals

As an individual investor, the admission of new ordinary shares and the reclassification process may impact you in several ways. Firstly, the consolidation of shares could result in a change in the total number of shares you hold in Hemogenyx Pharmaceuticals. Additionally, the increased efficiency in share distribution could lead to improved liquidity and potentially higher trading volumes, affecting the overall value of your investment. It is advisable to consult with your financial advisor to fully understand how these changes may affect your portfolio.

Global Implications

The admission of new ordinary shares and the subsequent capital reorganisation by Hemogenyx Pharmaceuticals reflects a growing trend in the biopharmaceutical industry towards strategic restructuring and efficiency enhancements. This move could potentially attract more investors to the sector, contributing to increased funding and innovation in the development of therapies for blood diseases on a global scale. Overall, the impact of this decision by Hemogenyx Pharmaceuticals may ripple through the industry, fostering growth and advancement in biopharmaceutical research and development.

Conclusion

In conclusion, Hemogenyx Pharmaceuticals’ admission of new ordinary shares and the capital reorganisation signify a pivotal moment in the company’s evolution, with promising outcomes for both individual investors and the global biopharmaceutical industry. By streamlining share distribution and fostering financial stability, Hemogenyx Pharmaceuticals is poised for continued growth and success in its mission to develop innovative therapies for blood diseases.